explore -WSS

explore

author：focus 2025-10-02 08:24:20 - browse：461

The FDA building -- First Opinion coverage from STAT — Adobe

A panel of independent advisers to the Food and Drug Administration voted overwhelmingly against a polarizing potential treatment for ALS on Wednesday, concluding that the medicine’s messy supporting data did not meet the standard for approval.

After a day-long meeting that included impassioned testimony from ALS patients, the agency’s expert advisers voted 17-1 with one abstention that the case for NurOwn, a treatment from BrainStorm Cell Therapeutics, was based too heavily on convoluted clinical trial results and compelling but unreliable anecdotal evidence.

“Patients and families need hope, but providing false hope can be ethically problematic,” said panelist Lisa Lee, a bioethicist at Virginia Tech. “False hope is provided when the probability of a positive outcome is overestimated, and I think that seems to be the case here.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Amid AI frenzy, a top HHS official's quest to create safeguards

WSS

New warning issued for rebooking air travel after delays, cancellations

TikTok cracks down on users posting about weight loss drugs

'Reaching a detente': STAT's Helen Branswell on covering Covid

WuXi out of biotech trade group, U.S. and China relations to blame

Russia strikes Ukraine's critical port facilities in Odesa after halting grain deal

Ebola: Gilead Sciences antiviral shows promise as new treatment

Wikipedia

explore

entertainment

Activists slam private health insurers over coverage restrictions

Medicare coverage of Wegovy, once blocked, now looks possible

United colonoscopy coverage change 'may cost lives,' doctors say

Stanford president to resign after investigation of research

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Sports medicine is finally prioritizing gender equality

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Hollywood unions extend contract negotiations for actors

Ebola: Gilead Sciences antiviral shows promise as new treatment

knowledge

As AI in medicine takes off, can 'human in the loop' prevent harm?

Why some people catch Covid but never get sick

First U.S. drug developed to treat liver disease MASH is approved

Ebola: Gilead Sciences antiviral shows promise as new treatment

Trump got a 'target letter.' What is one and what does it mean?

Man who had jail sentence commuted by Trump arrested again

hotspot

explore

knowledge

focus